Yao F. Xie

Beijing, 100015, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 133 publications

Efficacy and Safety of Avatrombopag in Patients with Chronic Liver Disease and Thrombocytopenia Undergoing Elective Surgery.

Efficacy and Safety of Avatrombopag in Patients with Chronic Liver Disease and Thrombocytopenia Undergoing Elective Surgery.

Journal: Journal of clinical medicine

Published: June 05, 2026

Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.

Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.

Journal: The New England journal of medicine

Published: May 28, 2026

Precision treatment and frontier advances of glycyrrhizin preparations in drug-induced liver injury (DILI).

Precision treatment and frontier advances of glycyrrhizin preparations in drug-induced liver injury (DILI).

Journal: Frontiers in pharmacology

Published: May 25, 2026

Impact of antiviral treatment and initiation time on mother-to-child transmission in pregnant women with extremely high HBV DNA loads.

Impact of antiviral treatment and initiation time on mother-to-child transmission in pregnant women with extremely high HBV DNA loads.

Journal: Virulence

Published: April 20, 2026

Staged soft tissue augmentation in multidisciplinary treatment of stage Ⅲ periodontitis: an 8-year follow-up case report

Staged soft tissue augmentation in multidisciplinary treatment of stage Ⅲ periodontitis: an 8-year follow-up case report

Journal: Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology

Published: March 31, 2026

Efficacy of NAs in combination with Peg-IFN for functional cure in patients with CHB: a meta-analysis of RCTs.

Efficacy of NAs in combination with Peg-IFN for functional cure in patients with CHB: a meta-analysis of RCTs.

Journal: Annals of medicine

Published: March 04, 2026

Analysis of risk factors and establishment of a predictive model for liver disease severity in metabolic dysfunction-associated fatty liver disease.

Analysis of risk factors and establishment of a predictive model for liver disease severity in metabolic dysfunction-associated fatty liver disease.

Journal: Frontiers in medicine

Published: February 07, 2026

Efficacy and Safety of Pegylated Interferon as Rescue Therapy for Patients with Chronic Hepatitis B Who Failed to Achieve Functional Cure After Antisense Oligonucleotides or Small Interfering RNA: A Prospective, Multicentre, Open-Label Randomized Controlled Trial (SPHERE) Protocol.

Efficacy and Safety of Pegylated Interferon as Rescue Therapy for Patients with Chronic Hepatitis B Who Failed to Achieve Functional Cure After Antisense Oligonucleotides or Small Interfering RNA: A Prospective, Multicentre, Open-Label Randomized Controlled Trial (SPHERE) Protocol.

Journal: Advances in therapy

Published: February 06, 2026

Lasso Regression-based Model for Cross-Sectional Identification of Significant Hepatic Fibrosis in NAFLD LASSO-based identification of hepatic fibrosis in NAFLD.

Lasso Regression-based Model for Cross-Sectional Identification of Significant Hepatic Fibrosis in NAFLD LASSO-based identification of hepatic fibrosis in NAFLD.

Journal: Biomedical and environmental sciences : BES

Published: January 20, 2026

The clinical significance and optimization strategies of HBeAg seroclearance in chronic hepatitis B treatment.

The clinical significance and optimization strategies of HBeAg seroclearance in chronic hepatitis B treatment.

Journal: Frontiers in cellular and infection microbiology

Published: January 11, 2026

Beyond viral suppression: combining PEG-interferon with novel immunotherapies for functional cure of chronic hepatitis B.

Beyond viral suppression: combining PEG-interferon with novel immunotherapies for functional cure of chronic hepatitis B.

Journal: Frontiers in cellular and infection microbiology

Published: January 01, 2026

HBsAg loss in chronic hepatitis B patients with an HBsAg decline plateau can be enhanced by intermittent PEG-IFN treatment.

HBsAg loss in chronic hepatitis B patients with an HBsAg decline plateau can be enhanced by intermittent PEG-IFN treatment.

Journal: Frontiers in cellular and infection microbiology

Published: December 30, 2025

Showing 1-12 of 133

Last Updated: 09/26/2026